Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Incyte Corporation
Constellation Pharmaceuticals
AbbVie
M.D. Anderson Cancer Center
University of Nebraska
University of Washington
Takeda
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Groupe Francophone des Myelodysplasies
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology
Incyte Corporation
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Traws Pharma, Inc.
Baylor College of Medicine
Polyphor Ltd.
Memorial Sloan Kettering Cancer Center
Humanigen, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Asan Medical Center
M.D. Anderson Cancer Center
Baylor College of Medicine
Northwestern University
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center